Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137685

Published: 2020

Journal Articles

Clinical Outcomes Following Treatment with Gilteritinib or Quizartinib in Patients with Relapsed/Refractory FLT3 -ITD+ Acute Myeloid Leukemia

Alexander E. Perl, MD, Qiaoyang Lu, MS, Alan Fan, MS Pharm, Nahla Hasabou, MD, Erhan Berrak, MD, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136118

Published: 2020

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Naval Daver, MD, Jessica K. Altman, MD, Joseph Maly, MD, Mark Levis, MD PhD, Ellen Ritchie, MD, Mark Litzow, MD, James K. McCloskey, MD, Catherine C. Smith, MD, Gary J. Schiller, MD, Terrence Bradley, MD, Ramon V. Tiu, MD, Wan-Jen Hong, MD, Bo Tong, PhD, Qin Qin, MS, Kimberley Dilley, MD MPH, Alexander E. Perl, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-139705

Published: 2020

Journal Articles

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Alexander E. Perl, MD, Jessica K. Altman, MD, Naoko Hosono, MD PhD, Pau Montesinos, MD PhD, Nikolai A. Podoltsev, MD PhD, Giovanni Martinelli, MD, Catherine C. Smith, MD, Mark Levis, MD PhD, Christoph Röllig, Prof., MD, Marco Groß-Langenhoff, PhD, Nahla Hasabou, MD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-136395

Published: 2020

Journal Articles

Clinical Evaluation of Xpert® BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1

Michael J. Mauro, MD, Richard D. Press, MD PhD, David S. Snyder, MD, Qin Huang, MD PhD, Javier Pinilla-Ibarz, Dahui Qin, MD PhD, Christina Lockwood, PhD, Jacqueline E. Payton, MD PhD, Geoffrey L. Uy, MD, Matt E. Kalaycio, MD, Ramon V. Tiu, MD BS, Vivian Oehler, MD, Gwo-Jen Day, PhD, Wendy Wong, Michael P. Bates, MD, Jerald P. Radich

Blood (2015) 126 (23): 5170.

https://doi.org/10.1182/blood.V126.23.5170.5170

Published: 2015

Journal Articles

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

Saroj Vadhan-Raj, MD, Rafat Abonour, Jonathan W. Goldman, MD, David A. Smith, MD, Christopher A. Slapak, MD, Ramon V. Tiu, MD, Xuejing Wang, Sophie Callies, Joanne Cox, Jay L. Tuttle, PhD, Yiu-Keung (James) Lau, MD PhD, Eric J. Roeland, MD

Blood (2015) 126 (23): 537.

https://doi.org/10.1182/blood.V126.23.537.537

Published: 2015

Journal Articles

Somatic Mutations in the Wiskott-Aldrich Syndrome Protein Family Member 3 ( WASF3 ) Are Associated with Poor Prognosis in Myeloid Malignancies

Valeria Visconte, PhD, Ali Tabarroki, MD, Li Zhang, Aaron T. Gerds, MD MS, Heesun J. Rogers, MD PhD, Velizar Shivarov, MD, PhD, John Barnard, Ramon V. Tiu, MD

Blood (2014) 124 (21): 4600.

https://doi.org/10.1182/blood.V124.21.4600.4600

Published: 2014

Journal Articles

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Ali Tabarroki, MD, Daniel Lindner, MD PhD, Valeria Visconte, PhD, Nikolaos Papandantonakis, Jing Ai, MD PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD, Matt E. Kalaycio, MD, Tracy Cinalli, RN, Kristin Colaluca, RN, Gina Rupp, John Desamito, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 4587.

https://doi.org/10.1182/blood.V124.21.4587.4587

Published: 2014

Journal Articles

Impact of Non- JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib

Jing Ai, MD PhD, Valeria Visconte, PhD, Ali Tabarroki, MD, Ahmad Zarzour, MD, Christopher Gerace, Karam Al-Issa, MD, Evan Hsi, Yasmine Hirbawi, Betty K. Hamilton, MD, Eric D. Hsi, MD, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 3194.

https://doi.org/10.1182/blood.V124.21.3194.3194

Published: 2014

Journal Articles

Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib

Ahmad Zarzour, MD, Ali Tabarroki, MD, Valeria Visconte, PhD, Rokana Taftaf, MD, Heesun J. Rogers, MD PhD, Jing Ai, MD PhD, Nikolaos Papadantonakis, MD PhD, Alan E. Lichtin, Yogen Saunthararajah, MD, Brady L Stein, MDMHS, Ramon V. Tiu, MD

Blood (2014) 124 (21): 1834.

https://doi.org/10.1182/blood.V124.21.1834.1834

Published: 2014

Journal Articles

Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib

Ahmad Zarzour, MD, Ali Tabarroki, MD, Rokana Taftaf, MD, Valeria Visconte, PhD, Jing Ai, MD PhD, Betty K. Hamilton, MD, Nikolaos Papadantonakis, MD PhD, Alan E. Lichtin, Leonard J. Horwitz, MD, Anjali S. Advani, MD, Mikkael A. Sekeres, MD MS, Ramon V. Tiu, MD

Blood (2014) 124 (21): 1835.

https://doi.org/10.1182/blood.V124.21.1835.1835

Published: 2014

Journal Articles

Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia

Valeria Visconte, PhD, Ali Tabarroki, MD, Christopher Gerace, Karam Al-Issa, MD, Eric D. Hsi, MD, Heesun J. Rogers, MD PhD, Mikkael A. Sekeres, MD MS, Bernard J. Silver, MD, Alan E. Lichtin, MD, Sudipto Mukherjee, MD MPH, Ramon V. Tiu, MD

Blood (2014) 124 (21): 5597.

https://doi.org/10.1182/blood.V124.21.5597.5597

Published: 2014

Journal Articles

Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1 ), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q)

Valeria Visconte, PhD, Ali Tabarroki, MD, John Barnard, Li Zhang, Juraj Bodo, PhD, Reda Mahfouz, MD, Betty K. Hamilton, MD, Mikkael Sekeres, Anjali S. Advani, MD, Matt E. Kalaycio, MD, Yogen Saunthararajah, MD, Velizar Shivarov, MD, PhD, Shashirekha Shetty, PhD, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 3250.

https://doi.org/10.1182/blood.V124.21.3250.3250

Published: 2014

Journal Articles

Triple Negative (J AK2 exon 12 /14 and MPL wild type) Myelofibrosis Have Higher Expression Of CDC25A and Greater Sensitivity To CDC25A Inhibition Compared To JAK2 Mutant Cases

Ali Tabarroki, MD, Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, Juraj Bodo, PhD, Li Zhang, Felicitas Lacbawan, Edy Hasrouni, John Barnard, Alan E. Lichtin, Daniel Lindner, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 5259.

https://doi.org/10.1182/blood.V122.21.5259.5259

Published: 2013

Journal Articles

Familial Mastocytosis: Identification Of KIT K509I Mutation and Its In Vitro Sensitivity To Imatinib, Dasatinib and PKC412

Paula De Melo Campos, MD, João Agostinho Machado-Neto, MSc, Adriana Silva Santos Duarte, PhD, Renata Scopim-Ribeiro, BSc, Flavia Fonseca de Carvalho Barra, MD, José Vassallo, MD, PhD, Irene Lorand-Metze, MD, PhD, Ramon V. Tiu, MD, Fernando Ferreira Costa, MD, PhD, Sara T O Saad, MD, PhD, Fabiola Traina, M.D., Ph.D.

Blood (2013) 122 (21): 5267.

https://doi.org/10.1182/blood.V122.21.5267.5267

Published: 2013

Journal Articles

Spliceosome Mutations Are Frequent In Patients With Myelodysplastic Syndromes Who Failed Hypomethylating Therapy: Possible Implications Of Spliceosome Inhibitors As Alternative Treatments

Valeria Visconte, PhD, Fabiola Traina, MD, PhD, Ali Tabarroki, MD, Edy Hasrouni, Jing Ai, MD, PhD, Matt Kalaycio, MD, Anjali S. Advani, MD, Hien K. Duong, MD, Yogen Saunthararajah, M.D., John Barnard, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD

Blood (2013) 122 (21): 5237.

https://doi.org/10.1182/blood.V122.21.5237.5237

Published: 2013

Journal Articles

LFA-3/CD2 Pathway, Potential Target For Immunosuppressive Therapy In Aplastic Anemia: A Phase I/II Trial Of Alefacept In Patients With Relapsed/Refractory Aplastic Anemia

Ramon V. Tiu, MD, Valeria Visconte, PhD, Paul Elson, Michael J. Clemente, Ali Tabarroki, MD, Edy Hasrouni, Amy Porter, Lindsey Mooney, Manuel G. Afable, II, Ricki Englehaupt, Joy Juersivich, RN, MSc, Kathleen Cooper, RN, MSc, Mikkael A. Sekeres, MD, MS, Yogen Saunthararajah, M.D., Jaroslaw P. Maciejewski, MD, PhD

Blood (2013) 122 (21): 3711.

https://doi.org/10.1182/blood.V122.21.3711.3711

Published: 2013

Journal Articles

Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations

Jing Ai, MD, PhD, Valeria Visconte, PhD, Ali Tabarroki, MD, Edy Hasrouni, Betty K. Hamilton, MD, Sudipto Mukherjee, MD, PhD, MPH, Matt Kalaycio, MD, Ronald M. Sobecks, MD, Anjali S. Advani, MD, Mikkael A. Sekeres, MD, MS, Shashirekha Shetty, PhD, Ramon V. Tiu, MD

Blood (2013) 122 (21): 2809.

https://doi.org/10.1182/blood.V122.21.2809.2809

Published: 2013

Journal Articles

Risk Of Acute and Chronic Leukemias Following Radiation Treatment For Locoregional Prostate Cancer In The United States Over 35-Years

Sudipto Mukherjee, MD, PhD, MPH, Chandana A. Reddy, Jay P. Ciezki, MD, Ramon V. Tiu, MD, Anjali S. Advani, MD, Yogen Saunthararajah, MD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Brian J. Bolwell, MD, Matt Kalaycio, MD, Eric A. Klein, MD, Mikkael A. Sekeres, MD, MS

Blood (2013) 122 (21): 2652.

https://doi.org/10.1182/blood.V122.21.2652.2652

Published: 2013

Journal Articles

Association Of Large Granular Lymphocytic Leukemia (LGL) With B-Cell Lymphoproliferative Disorders

Alan P. Z. Skarbnik, MD, Craig A. Portell, MD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Ramon V. Tiu, MD, Brad Pohlman, MD, Manuel G. Afable, II, Anjali S. Advani, MD, Robert M Dean, MD, Brian T. Hill, MD, PhD, Leonard J. Horwitz, MD, Deepa Jagadeesh, MD, MPH, Alan E. Lichtin, Christy Samaras, DO, Mikkael A. Sekeres, MD, MS, Michael Millenson, MD, Mitchell R Smith, MD, PhD

Blood (2013) 122 (21): 1387.

https://doi.org/10.1182/blood.V122.21.1387.1387

Published: 2013

NARROW

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Clinical Outcomes Following Treatment with Gilteritinib or Quizartinib in Patients with Relapsed/Refractory FLT3 -ITD+ Acute Myeloid Leukemia

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Clinical Evaluation of Xpert® BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

Somatic Mutations in the Wiskott-Aldrich Syndrome Protein Family Member 3 ( WASF3 ) Are Associated with Poor Prognosis in Myeloid Malignancies

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Impact of Non- JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib

Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib

Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib

Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia

Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1 ), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q)

Triple Negative (J AK2 exon 12 /14 and MPL wild type) Myelofibrosis Have Higher Expression Of CDC25A and Greater Sensitivity To CDC25A Inhibition Compared To JAK2 Mutant Cases

Familial Mastocytosis: Identification Of KIT K509I Mutation and Its In Vitro Sensitivity To Imatinib, Dasatinib and PKC412

Spliceosome Mutations Are Frequent In Patients With Myelodysplastic Syndromes Who Failed Hypomethylating Therapy: Possible Implications Of Spliceosome Inhibitors As Alternative Treatments

LFA-3/CD2 Pathway, Potential Target For Immunosuppressive Therapy In Aplastic Anemia: A Phase I/II Trial Of Alefacept In Patients With Relapsed/Refractory Aplastic Anemia

Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations

Risk Of Acute and Chronic Leukemias Following Radiation Treatment For Locoregional Prostate Cancer In The United States Over 35-Years

Association Of Large Granular Lymphocytic Leukemia (LGL) With B-Cell Lymphoproliferative Disorders

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only